Baseline characteristics among the three groups were well-matched for age, gender, body mass index, duration since diagnosis, prior use of any therapies (DMARDs, biologics, steroids) and clinical scores indicating disease activity
For investigational peptides, BPC-157 has the most direct preclinical evidence specifically for bone defect healing, with the Sebecic rabbit study showing complete bony continuity in treated animals while controls remained unhealed
It is a combination stack of two tissue-repair peptides: BPC-157 (Body Protection Compound-157) and TB-500 (Thymosin Beta-4)
Metabolism and weight management benefits typically become noticeable within 3-4 weeks of consistent treatment
Some are included in the package, while others are billed separately as optional upgrades
The name reflects both the skin improvements users report and the acronym-adjacent grouping of Growth (GHK-Cu), Localized healing (BPC-157), and Overall repair (TB-500 and Wolverine)
